New hope for Hard-to-Treat lung cancer: drug combo may make surgery possible
NCT ID NCT07573696
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving alectinib (a targeted pill) along with standard chemotherapy can shrink unresectable stage III ALK-positive lung cancer enough to allow surgery or radiation. About 50 people who have not had prior treatment will receive three cycles of the combination. If the tumor shrinks enough, they may have surgery or radiation, followed by more alectinib. The goal is to see if this strategy improves long-term cancer control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alectinib (a targeted cancer drug) plus platinum-based chemotherapy
What this could lead to
If successful, this approach could shrink tumors enough to allow surgery or radiation, potentially improving long-term control of stage III ALK-positive lung cancer.
What could go wrong
This is an early phase 2 trial with only 50 people, so results may not apply broadly. The combination may cause significant side effects, and not all participants will become eligible for local treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••